XML 107 R44.htm IDEA: XBRL DOCUMENT
v3.19.3

Summary of Significant Accounting Policies - Additional Information (Detail) |  |  |  |  | 3 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | ---
Nov. 20, 2019 USD ($) | Oct. 01, 2018 USD ($) | Jul. 31, 2018 USD ($) | Mar. 22, 2017 USD ($) | Sep. 28, 2019 USD ($) Customer | Mar. 30, 2019 USD ($) | Mar. 31, 2018 USD ($) | Sep. 30, 2017 USD ($) | Apr. 01, 2017 | Sep. 28, 2019 USD ($) Customer | Sep. 29, 2018 USD ($) Customer | Sep. 30, 2017 USD ($) | Sep. 26, 2015 USD ($) | Dec. 11, 2017 USD ($)
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from sale of business |  |  |  |  |  |  |  |  |  | $ 0 | $ 0 | $ 1,865,000,000.0 |  |
Impairment of intangible assets and equipment |  |  |  |  | $ 241,600,000 | $ 443,800,000 | $ 46,000,000.0 |  |  | 106,700,000 | 46,000,000.0 | 0 |  |
Goodwill impairment charge |  |  |  |  |  |  | 685,700,000 |  |  | $ 0 | 685,700,000 | 0 |  |
Cash Equivalents Maturity Period |  |  |  |  |  |  |  |  |  | three months or less |  |  |  |
Gross Carrying Value |  |  |  |  | $ 4,786,600,000 |  |  |  |  | $ 4,786,600,000 | $ 5,571,800,000 |  |  |
Number of customers with balance greater than specified percentage | Customer |  |  |  |  | 0 |  |  |  |  | 0 | 0 |  |  |
Accumulated Amortization |  |  |  |  | $ 3,326,800,000 |  |  |  |  | $ 3,326,800,000 | $ 3,173,200,000 |  |  |
Goodwill |  |  |  |  | 2,563,700,000 |  |  |  |  | 2,563,700,000 | 2,533,200,000 |  |  |
Other-than-temporary impairment charges |  |  |  |  |  |  |  | $ 0 |  |  |  |  |  |
Purchase of interest rate caps |  |  |  |  |  |  |  |  |  | 1,500,000 | 3,700,000 | 1,900,000 | $ 13,200,000 |
Principal amount of borrowings |  |  |  |  | 1,000,000,000.0 |  |  |  |  | 1,000,000,000.0 |  |  |  |
Loss reclassified from accumulated other comprehensive loss to the statement of operations, net |  |  |  |  |  |  |  |  |  | 3,100,000 | 3,600,000 | 6,900,000 |  |
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred |  |  |  |  |  |  |  |  |  | 2,300,000 |  |  |  |
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments |  |  |  |  |  |  |  |  |  | 11,000,000.0 | 1,300,000 | 3,100,000 |  |
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax |  |  |  |  |  |  |  |  |  | 2,200,000 | 6,600,000 | 3,600,000 |  |
Notional Amount |  |  |  |  | 104,200,000 |  |  |  |  | $ 104,200,000 |  |  |  |
Product Warranty Term |  |  |  |  |  |  |  |  |  | 1 year |  |  |  |
Advertising cost |  |  |  |  |  |  |  |  |  | $ 29,500,000 | 26,900,000 | 22,500,000 |  |
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax |  |  |  |  |  |  |  |  |  | 3,100,000 | 4,000,000.0 |  |  |
Increase to cash flows used in financing activities |  |  |  |  |  |  |  |  |  | 280,700,000 | 195,200,000 | (285,800,000) |  |
Accelerated Depreciation |  |  |  |  |  |  |  |  |  |  | 5,900,000 | $ 3,000,000.0 |  |
Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross Carrying Value |  |  |  |  | 3,927,700,000 |  |  |  |  | 3,927,700,000 | 4,573,300,000 |  |  |
Accumulated Amortization |  |  |  |  | 2,654,800,000 |  |  |  |  | 2,654,800,000 | 2,505,800,000 |  |  |
Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross Carrying Value |  |  |  |  | 245,400,000 |  |  |  |  | 245,400,000 | 312,500,000 |  |  |
Accumulated Amortization |  |  |  |  | 171,100,000 |  |  |  |  | 171,100,000 | 175,000,000.0 |  |  |
In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross Carrying Value |  |  |  |  | 0 |  |  |  |  | 0 | 5,500,000 |  |  |
Accumulated Amortization |  |  |  |  | 0 |  |  |  |  | $ 0 | 0 |  |  |
Minimum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets useful life |  |  |  |  |  |  |  |  |  | 2 years |  |  |  |
Transition services agreement term |  |  |  |  |  |  |  |  | 2 years |  |  |  |  |
Minimum | Accounts receivable [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  | 10.00% |  | 10.00% |  |  |  |
Minimum | Total revenues [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Concentration risk, percentage |  |  |  |  |  |  |  | 10.00% |  | 10.00% |  | 10.00% |  |
Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets useful life |  |  |  |  |  |  |  |  |  | 30 years |  |  |  |
Transition services agreement term |  |  |  |  |  |  |  |  | 3 years |  |  |  |  |
Equity Securities [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax |  |  |  |  |  |  |  |  |  |  | 400,000 |  |  |
Interest rate caps - derivative |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Interest rate caps - derivative |  |  |  |  | 100,000 |  |  |  |  | $ 100,000 | 7,700,000 |  |  |
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax |  |  |  |  |  |  |  |  |  | 3,100,000 | 3,600,000 |  |  |
Focal Therapeutics |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  | $ 31,100,000 |  |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  | 83,100,000 |  |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics | Trade Names [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  | 2,700,000 |  |  |  |  |  |  |  |  |  |  |  |
Focal Therapeutics | In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  | $ 11,400,000 |  |  |  |  |  |  |  |  |  |  |  |
In process research and development reclassified to developed technology |  |  |  |  |  |  |  |  |  | 5,500,000 |  |  |  |
Cynosure |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairment charge |  |  |  |  |  |  | 685,700,000 |  |  |  |  |  |  |
Goodwill |  |  |  | $ 685,700,000 |  |  |  |  |  |  |  |  |  |
Cynosure | Developed Technology Rights [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Impairment charge |  |  |  |  |  |  | 46,000,000.0 |  |  |  |  |  |  |
Cynosure | In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  |  |  | $ 107,000,000.0 |  |  |  |  |  |  |  |  |  |
Cynosure | Goodwill [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill impairment charge |  |  |  |  |  |  | $ 685,700,000 |  |  |  |  |  |  |
Emsor |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 4,600,000
Goodwill |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 5,700,000
Faxitron |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible assets |  |  |  |  |  |  |  |  |  |  | 53,400,000 |  |  |
Goodwill |  |  | $ 45,600,000 |  |  |  |  |  |  |  |  |  |  |
Medical Aesthetics |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  | 0 |  |  |  |  | 0 | $ 0 |  |  |
Operating Segments [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Goodwill |  |  |  |  | $ 2,600,000,000 |  |  |  |  | $ 2,600,000,000 |  |  |  |
Accounting Standards Update 2016-09 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase to cash flows used in financing activities |  |  |  |  |  |  |  | $ 11,000,000 |  |  |  | $ 10,700,000 |  |
Forward foreign currency contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Derivative contract period, or less |  |  |  |  |  |  |  |  |  | 1 year |  |  |  |
Measurement Input, Discount Rate | Focal Therapeutics | Minimum | In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  | 15.50% |  |  |  |  |  |  |  |  |  |  |  |
Measurement Input, Discount Rate | Focal Therapeutics | Maximum | In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  | 16.50% |  |  |  |  |  |  |  |  |  |  |  |
Measurement Input, Discount Rate | Cynosure | Minimum | Other intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  |  | 11.00% |  |  |  |  |  |  |  |  |  |
Measurement Input, Discount Rate | Cynosure | Minimum | In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  |  | 14.00% |  |  |  |  |  |  |  |  |  |
Measurement Input, Discount Rate | Cynosure | Maximum | Other intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  |  | 12.00% |  |  |  |  |  |  |  |  |  |
Measurement Input, Discount Rate | Cynosure | Maximum | In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  |  | 22.00% |  |  |  |  |  |  |  |  |  |
Measurement Input, Discount Rate | Faxitron | Minimum | In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  | 17.00% |  |  |  |  |  |  |  |  |  |  |
Measurement Input, Discount Rate | Faxitron | Maximum | In-process research and development |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  | 19.00% |  |  |  |  |  |  |  |  |  |  |
Measurement Input, Discount Rate | Medical Aesthetics | Cynosure | Maximum | Other intangible assets |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fair value, discount rate |  |  |  | 12.00% |  |  |  |  |  |  |  |  |  |
Subsequent Event | Medical Aesthetics Business |  |  |  |  |  |  |  |  |  |  |  |  |  |
Significant Accounting Policies [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proceeds from sale of business | $ 205,000,000.0 |  |  |  |  |  |  |  |  |  |  |  |  |
Sales price | $ 138,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |

X
- Definition Accelerated Depreciation + References No definition available. + Details
Name: | holx_AcceleratedDepreciation
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value + References No definition available. + Details
Name: | holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValue
Namespace Prefix: | holx_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of time from the date of acquisition for liquid investments in debt securities to be categorized as cash in the consolidated balance sheet. + References No definition available. + Details
Name: | holx_CashEquivalentsMaturityPeriod
Namespace Prefix: | holx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition In process research and development reclassified to developed technology + References No definition available. + Details
Name: | holx_Inprocessresearchanddevelopmentreclassifiedtodevelopedtechnology
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Interest rate cap agreements aggregate premium payable. + References No definition available. + Details
Name: | holx_InterestRateCapAgreementsAggregatePremiumPayable
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Notional Amount + References No definition available. + Details
Name: | holx_NotionalAmount
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of customers with balance greater than specified percentage. + References No definition available. + Details
Name: | holx_NumberOfCustomersWithBalanceGreaterThanSpecifiedPercentage
Namespace Prefix: | holx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the aggregate outstanding principal of amounts borrowed under the Credit Agreement. + References No definition available. + Details
Name: | holx_PrincipalAmountOfBorrowings
Namespace Prefix: | holx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition [Line Items] for Significant Accounting Policies [Table] + References No definition available. + Details
Name: | holx_SignificantAccountingPoliciesLineItems
Namespace Prefix: | holx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Transition Services Agreement Term + References No definition available. + Details
Name: | holx_TransitionServicesAgreementTerm
Namespace Prefix: | holx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Warranty Term For Products + References No definition available. + Details
Name: | holx_WarrantyTermForProducts
Namespace Prefix: | holx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 720 -SubTopic 35 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848 + Details
Name: | us-gaap_AdvertisingExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228 + Details
Name: | us-gaap_AssetImpairmentCharges
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of intangible assets, excluding goodwill, acquired at the acquisition date. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=84161108&loc=d3e4845-128472 + Details
Name: | us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13531-108611 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109250915&loc=d3e13537-108611 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition This item represents an other than temporary decline in value that has been recognized against an investment accounted for under the cost method of accounting. The excess of the carrying amount over the fair value of the investment represents the amount of the write down which is or was reflected in earnings. The written down value is a new cost basis with the adjusted value of the investment becoming its new carrying value. Evidence of a loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the investee to sustain an earnings capacity which would justify the carrying amount of the investment. + References No definition available. + Details
Name: | us-gaap_CostmethodInvestmentsOtherThanTemporaryImpairment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 30 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=112277219&loc=d3e80845-113994 + Details
Name: | us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_DerivativeTermOfContract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + References No definition available. + Details
Name: | us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 928 -SubTopic 340 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959 + Details
Name: | us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266 + Details
Name: | us-gaap_Goodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 2 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266 + Details
Name: | us-gaap_GoodwillImpairmentLoss
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 3 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3602-108585 + Details
Name: | us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Fair value as of the balance sheet date of all interest rate derivative assets designated as cash flow hedging instruments. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4B -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959 + Details
Name: | us-gaap_InterestRateCashFlowHedgeAssetAtFairValue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3521-108585 + Details
Name: | us-gaap_NetCashProvidedByUsedInInvestingActivities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph c -URI http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 17A -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL34724391-108580 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e689-108580 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=114867106&loc=d3e637-108580 + Details
Name: | us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromDivestitureOfBusinesses
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount after tax of reclassification adjustments of other comprehensive income (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 17B -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL34724394-108580 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -URI http://asc.fasb.org/extlink&oid=114867106&loc=SL7669686-108580 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 55 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=109228884&loc=d3e1436-108581 + Details
Name: | us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959 + Details
Name: | us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=holx_RevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FinancialInstrumentAxis=us-gaap_InterestRateCapMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_FocalTherapeuticsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_CynosureMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_GoodwillMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_EmsorMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=holx_FaxitronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=holx_MedicalAestheticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=holx_MedicalAestheticsBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |